image-title

ONCOLYTICS TODAY

Completes BPA Worldwide Initial Business Publication Audit

SHELTON, CT, 10/5/20 – Oncolytics Today has completed its BPA Worldwide business publication audit.

Glenn J. Hansen, BPA Worldwide President, praised Oncolytics Today for voluntarily opening its records to independent verification and documentation of its circulation data.

Hansen pointed out that the audit facilitates the buying and selling of advertising space. A BPA Worldwide report provides advertisers and agencies with assurance that what they choose to invest in does, in fact, reach target audiences for specific ads. The BPA Worldwide audit also helps media companies by documenting the quality of their audiences.

Copies of the initial BPA Worldwide audit report for Oncolytics Today are available from BPA Worldwide or the publisher.

Oncolytics Today will be issuing semi-annual Brand Reports.

BPA Worldwide conducts its circulation audits on an annual basis following accepted auditing procedures. In addition to verifying exact counts of recipients, BPA Worldwide also documents that they are qualified in the markets served by the publications.

View the full Press Release HERE.

Read More
image-title

MISSION STATEMENT/PHILOPSOPHY:

To meet patients wherever they are on their cancer journey and walk with them on that journey; to provide compassionate, personalized cancer care for an unparalleled patient experience.

LOCATIONS:

Coeur D’ Alene, ID

PRACTICE DETAILS (how many providers, how many employees, etc):

3 MO/DO

2 ARNP

20-25 employees

INTRODUCTION TO PHARMACY SERVICES STAFF W/ BRIEF BIO:

From Left to Right: Nicole Davis CPhT Oral Chemotherapy, Beverly Ward PharmD, Valerie Frodin CPhT IV Infusions)

DISPENSING TYPE (RETAIL VS DISPENSARY):

Medically Integrated Dispensing (MID)

SERVICES PROVIDED (BONE MARROW, RADIATION, CHEMO):

Patient Centered Care

IV Chemo Infusions

On-site MID

Genetic Testing

Clinical Trials

Nutrition Counseling

Financial Counseling

WHY DID  YOU JOIN NCODA?

I was shown NCODA by a fellow member and I appreciated all of the resources NCODA offered.

HOW DID YOU HEAR ABOUT US?

Referred by a team member.

HOW CAN NCODA HELP YOU?

By assisting Beacon in our Mission to provide the highest quality patient centered care with treatment support kits, education and the latest news in oncology.

HOW WOULD YOU LIKE TO BE MORE INVOLVED WITH NCODA?

Encouraging more co-workers to join NCODA, everyone can benefit!

WHAT ARE SOME CHALLENGES YOU FACE NOW OR WILL FACE IN THE FUTURE OF ONCOLOGY?

Being a newly opened, smaller clinic can be challenging in an environment where privately owned clinics are dwindling. NCODA offers the support we need to have the latest news in treatment and great support and education options for patients.

 

Read More

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.4 months). The data for the analysis of overall survival were immature at the time of the primary analysis. Read the full article HERE or download HERE.

Read More

CAMBRIDGE, Mass., September 4, 2020 – Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved GAVRETO™ (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. The approval is based on data from the Phase 1/2 ARROW clinical trial, which showed efficacy for GAVRETO in patients with RET fusion-positive NSCLC with or without prior therapy, and regardless of RET fusion partner or central nervous system involvement. Under Blueprint Medicines’ collaboration with Roche, Blueprint Medicines and Genentech, a member of the Roche Group, will co-commercialize GAVRETO in the U.S. GAVRETO is a once-daily oral RET-targeted therapy developed by Blueprint Medicines. It is designed to selectively and potently inhibit RET alterations that drive many cancer types, including approximately 1 to 2 percent of patients with NSCLC. Currently, RET is one of seven NSCLC biomarkers that can be targeted with an FDA-approved therapy. See the full Press Release HERE

To view GAVRETO’s product website, please visit www.GAVRETOHCP.com

To review the full Prescribing Information for GAVRETO, please click https://www.blueprintmedicines.com/uspi/GAVRETO.pdf

Read More

The industry-leading continuing pharmacy education provider becomes sole provider for association’s three major meetings through 2021

(CRANBURY, N.J. – August 23, 2020) – PTCE proudly announces it is now the exclusive continuing education (CE) provider for the National Community Oncology Dispensing Association, Inc. (NCODA) 2020-2021 meetings.

See Full Press Release here

Read More